StreetInsider.com News Articles

Increasing unusual call option volume: GDS AM PGEN DFTX CTSH SWKS AIG BFLY OTLK EH CABA

Tue, 23 Jun 2026 03:36:44 -0400

Increasing unusual call option volume: GDS AM PGEN DFTX CTSH SWKS AIG BFLY OTLK EH CABA

Form 8-K Cabaletta Bio, Inc. For: Jun 09

Thu, 11 Jun 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26632460.html

Form 8-K Cabaletta Bio, Inc. For: Jun 09

Thu, 11 Jun 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26632460.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: Tomasello Shawn

Wed, 10 Jun 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260610/26631187.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: Tomasello Shawn

Wed, 10 Jun 2026 19:04:00 -0400

si-local-file:///var/storage/secattach/20260610/26631187.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: Simon Mark

Wed, 10 Jun 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260610/26631175.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: Simon Mark

Wed, 10 Jun 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260610/26631175.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: HENRIQUES RICHARD C JR

Wed, 10 Jun 2026 18:56:00 -0400

si-local-file:///var/storage/secattach/20260610/26631168.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: HENRIQUES RICHARD C JR

Wed, 10 Jun 2026 18:56:00 -0400

si-local-file:///var/storage/secattach/20260610/26631168.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: Bollard Catherine

Wed, 10 Jun 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260610/26631163.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: Bollard Catherine

Wed, 10 Jun 2026 18:54:00 -0400

si-local-file:///var/storage/secattach/20260610/26631163.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: Brun Scott C.

Wed, 10 Jun 2026 18:51:00 -0400

si-local-file:///var/storage/secattach/20260610/26631155.html

Form 4 Cabaletta Bio, Inc. For: Jun 09 Filed by: Brun Scott C.

Wed, 10 Jun 2026 18:51:00 -0400

si-local-file:///var/storage/secattach/20260610/26631155.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: PRUDENTIAL FINANCIAL INC

Fri, 05 Jun 2026 14:10:00 -0400

si-local-file:///var/storage/secattach/20260605/26610389.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: PRUDENTIAL FINANCIAL INC

Fri, 05 Jun 2026 14:10:00 -0400

si-local-file:///var/storage/secattach/20260605/26610389.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: JENNISON ASSOCIATES LLC

Thu, 04 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260604/26605981.html

Form SCHEDULE 13G/A Cabaletta Bio, Inc. Filed by: JENNISON ASSOCIATES LLC

Thu, 04 Jun 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260604/26605981.html

Jefferies on Cabaletta Bio (CABA): 'We came away from EULAR 2026 update increasingly positive on the wholistic resecel profile'

Wed, 03 Jun 2026 07:31:30 -0400

Jefferies analyst Roger Song reiterated a Buy rating and $14.00 price target on Cabaletta Bio (NASDAQ: CABA).

The analyst comments "Bottom line. We came away from EULAR 2026 update increasingly positive on the wholistic resecel profile, with the dataset continuing to reinforce the platform’s core value proposition—deep Bcell depletion translating into meaningful clinical responses that appear durable across multiple autoimmune indications. Four important things to note: 1) data is particularly supportive for the ongoing pivotal path in IIM, where response rates remain high and—critically—durability is now extending to ~1.5 years, well beyond the 16-week primary endpoint in the registrational study. This

Cabaletta Bio reports positive rese-cel data in autoimmune diseases

Wed, 03 Jun 2026 07:03:36 -0400

Cabaletta Bio Inc. (NASDAQ: CABA) announced clinical data for its investigational cell therapy rese-cel across multiple autoimmune diseases at the European Alliance of Associations for Rheumatology 2026 Congress in London.

In the Phase 1/2 RESET-Myositis study, 83% of dermatomyositis patients achieved moderate-to-major Total Improvement Score responses at 16 weeks after discontinuing immunomodulators. All five patients maintained responses through follow-up periods extending to 1.5 years. The company's first juvenile dermatomyositis patient demonstrated a moderate response maintained through 32 weeks of follow-up.

For systemic sclerosis, 83% of patients achieved revised Composite Response Index in Systemic Sclerosis-25 responses at 36 weeks while off immunomodulators. Patients

Cabaletta Bio reports positive rese-cel data in autoimmune diseases

Wed, 03 Jun 2026 07:03:36 -0400

For systemic sclerosis, 83% of patients achieved revised Composite Response Index in Systemic Sclerosis-25 responses at 36 weeks while off immunomodulators. Patients

Form 8-K Cabaletta Bio, Inc. For: Jun 03

Wed, 03 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260603/26595280.html

Form 8-K Cabaletta Bio, Inc. For: Jun 03

Wed, 03 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260603/26595280.html

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Wed, 03 Jun 2026 07:00:00 -0400

83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years

First juvenile dermatomyositis (JDM) patient demonstrated moderate TIS response off immunomodulators and maintained their response through latest follow-up at 32 weeks; JDM expected to be included in 2H27 myositis BLA submission, facilitating the potential for a priority review voucher

Systemic sclerosis (SSc) announced as second pivotal indication based on convincing Phase 1/2 data after a single dose of rese-cel upon

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Wed, 03 Jun 2026 07:00:00 -0400

83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years

First juvenile dermatomyositis (JDM) patient demonstrated moderate TIS response off immunomodulators and maintained their response through latest follow-up at 32 weeks; JDM expected to be included in 2H27 myositis BLA submission, facilitating the potential for a priority review voucher

Systemic sclerosis (SSc) announced as second pivotal indication based on convincing Phase 1/2 data after a single dose of rese-cel upon

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Wed, 03 Jun 2026 07:00:00 -0400

83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years

First juvenile dermatomyositis (JDM) patient demonstrated moderate TIS response off immunomodulators and maintained their response through latest follow-up at 32 weeks; JDM expected to be included in 2H27 myositis BLA submission, facilitating the potential for a priority review voucher

Systemic sclerosis (SSc) announced as second pivotal indication based on convincing Phase 1/2 data after a single dose of rese-cel upon